Chat with us, powered by LiveChat
skip to Main Content

CurveBeam AI HR-pQCT Wrist Scans

Automated Fragility Assessment

upload-icon

HR-pQCT platform provides consistent images, ensuring reliable AI results

FitsAnywhereIconWhite

HR-pQCT fits seamlessly into imaging centers, hospitals, and even the point of care setting, improving patient access for screening and monitoring therapy

HandIconTrans

Region of Interest selection is automated to further ensure consistency

CurveBeam AI’s DLAI tools are investigational only and are not available for sale in the United States.

RECEIVE MORE INFORMATION ABOUT THE HR-pQCT

Visualization-Hand

Automated Bone Fragility Analysis with OssView™

OssView™ Bone Fragility software analyzes high-resolution peripheral quantitative computed tomography (HR-pQCT) images at the distal radius to measure the bone microarchitecture. OssView assesses cortical and trabecular density, cortical thickness, and porosity to calculate a Structural Fragility Score (SFS). SFS, when used as a complement to traditional bone mineral density (BMD) tests, allows clinicians to detect fracture risk in non-osteoporotic women. Better diagnoses before a first fracture will help to avert mortality and morbidity consequences.

OssView has received Breakthrough Device Designation from the US FDA Breakthrough Devices Program. OssView is investigational only and is not available for sale in the United States.

The OssView™ Bone Fragility software is intended to be used as an aid in the clinical assessment of fracture risk in women 70 years and older. It is indicated to be used in women diagnosed as non-osteoporotic after a clinical exam using a bone densitometer.

Structural Fragility Score - A New Measure for Quantifying Fracture Risk

The Structural Fragility Score (SFS), delivered through OssView, is a measure of the deterioration of cortical and trabecular bone in an individual.  The measurement is quantified as a deviation or a degree of worsening of cortical porosity and trabecular density relative to the average values in healthy young women, and relative to each other.

This combination of indices indicates that bone loss and microstructural deterioration has occurred and that this is the cause of bone fragility, which is captured by the SFS.

OssView has received Breakthrough Device Designation from the FDA. It is investigational only and not available for sale in the United States.

ExampleOssviewPatientSheet

OPERATIONAL BENEFITS

News & Events

Back To Top
Search